An article about our company entitled " Stem cell-derived heart cells injected into first patient " was published in Nature Medicine on March 13, 2023.

Stem cell-derived heart cells injected into first patient

Nature Medicine explores the latest translational and clinical research news, with Heartseed and Novo Nordisk's clinical trial of iPSC-derived cardiomyocytes for the treatment of heart failure.

The full text is available here for a fee.

https://www.nature.com/articles/d41591-023-00027-5

The article mentions that Fukuda Group at Department of Cardiology, Keio University School of Medicine, has pioneered in producing clinical-grade cardiomyocytes from iPS cells, and that the group succeeded in optimizing the culture system by removing glucose and glutamine and adding lactate (mimicking the metabolic mechanism in the maturation process from fetal to neonatal cardiomyocytes) to eliminate undifferentiated pluripotent stem cells that can cause teratoma while promoting cardiomyocyte survival.

The article concludes with the nuance that the demand for this treatment is high and that there is still a way to go, but hopes for progress.

We take this article as a welcome message to Heartseed, which has been pursuing science.